World CDx 2026 has ended. This guide stays up as the record of who was there. Next: World CDx 2027, Aug 30 – Sep 2, 2027 in Boston

Who Went to World CDx 2026

Oct 5–8, 2026 Boston, MA ~900 attendees Website

120 organizations and 135 speakers at World CDx 2026, an ~850-person, mostly industry meeting of biomarker and companion diagnostics leaders. As of Oct 8, 2026.

Format
Topic
Top represented
Showing 1–10 of 120 organizations
OrganizationWorld CDx 2026 Attendance
jnj.com
Large pharma
Pharmaceutical business of Johnson & Johnson, formerly Janssen, with medicines in oncology, immunology and neuroscience.
Talk
Tue Oct 6
11:10am
From Strategic Partnering to Orchestrated Partnering: Navigating the Next Era of Precision Medicine
Drug–diagnostic commercialization & access
Panel
Tue Oct 6
6:10pm
Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation
with GSK, Bristol Myers Squibb, BLOODPAC
Liquid biopsy & MRDClinical & companion diagnostic development
Chair
Wed Oct 7
11:19am
Stream chair
Talk
Wed Oct 7
12:40pm
MRD in IBD? Building a Precision Medicine Consortium for Deeper Endpoints in IBD
with Crohn's & Colitis Foundation
Biomarker discovery & translation
Talk
Wed Oct 7
2:40pm
If You Build It, Will They Come?
Drug–diagnostic commercialization & access
Panel
Wed Oct 7
5:00pm
Beyond the Contract: Inside a Pharma–CDx Partnership
with Thermo Fisher Scientific
Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access
Talk
Thu Oct 8
8:10am
Expanding Access to Precision Cancer Care with the Precision Cancer Consortium CGP Implementation Guide
Drug–diagnostic commercialization & accessClinical & companion diagnostic development
Panel
Thu Oct 8
9:00am
Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers
with Bristol Myers Squibb, AstraZeneca
Drug–diagnostic commercialization & access
Panel
Thu Oct 8
2:00pm
Fit-for-Purpose CDx Strategies: Matching Testing Approaches to Development & Patient Access Needs​
with Labcorp
Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access
EMD Serono
Rockland, MA
emdserono.com
Large pharma
US and Canadian healthcare business of Merck KGaA, Darmstadt, developing medicines in oncology, neurology, immunology and fertility.
Talk
Tue Oct 6
11:30am
A Dual Tissue & Liquid Biopsy Strategy: The TEPMETKO® Companion Diagnostic Journey
with Foundation Medicine
Clinical & companion diagnostic developmentLiquid biopsy & MRD
Chair
Wed Oct 7
8:00am
Chair’s Opening Remarks
Talk
Wed Oct 7
11:50am
Definition of the Best Practices in Clinical Utility of Liquid Biopsy: Clinical Guideline, Technologies, Cost-Effectiveness, Reimbursement, a Unidirectional or Multidirectional Path
Liquid biopsy & MRDDrug–diagnostic commercialization & access
Panel
Wed Oct 7
12:50pm
Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation
with Merck, Eikon Therapeutics, Compass Therapeutics
Liquid biopsy & MRD
Chair
Wed Oct 7
4:05pm
Chair’s Opening Afternoon Remarks
Chair
Wed Oct 7
5:50pm
Closing Remarks & End of Conference Day Two
Merck
Rahway, NJ
merck.com
Large pharma
US pharmaceutical company, known as MSD outside the US and Canada, with oncology medicines including pembrolizumab.
Panel
Tue Oct 6
12:30pm
Companion Diagnostics from Biomarker Discovery to Global Launch: Building Better Partnerships Across Science, Regulation, & Commercialization
with Agilent, Tango Therapeutics
Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access
Talk
Tue Oct 6
2:30pm
Integrating Science & Strategy to Advance Companion Diagnostic Development for Optimal Patient Treatment
Clinical & companion diagnostic development
Panel
Wed Oct 7
12:50pm
Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation
with Eikon Therapeutics, Compass Therapeutics, EMD Serono
Liquid biopsy & MRD
Panel
Wed Oct 7
3:10pm
Advancing Regulatory Frameworks & Standards for Compliant Digital Pathology Co-Development
with Elevation Strategic Development
Digital pathology & spatial biomarkersClinical & companion diagnostic development
Talk
Thu Oct 8
12:20pm
A Single-Cell Platform for Linking CRISPR-Edited Variants to Transcriptional Outcomes
Biomarker discovery & translation
Talk
Thu Oct 8
12:20pm
Drug Diagnostic Co-Development: Overlooked Challenges & Mitigations
Clinical & companion diagnostic development
◇Expertise Partner
thermofisher.com
Instruments & reagentsExpertise Partner
Supplies instruments, reagents and services for translational research and companion diagnostic development through brands including Applied Biosystems, Invitrogen and Ion Torrent.
Panel
Wed Oct 7
5:00pm
Beyond the Contract: Inside a Pharma–CDx Partnership
with Johnson & Johnson Innovative Medicine
Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access
bms.com
Large pharma
Global pharmaceutical company with medicines in oncology, hematology, immunology and cardiovascular disease.
Panel
Tue Oct 6
6:10pm
Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation
with GSK, Johnson & Johnson Innovative Medicine, BLOODPAC
Liquid biopsy & MRDClinical & companion diagnostic development
Panel
Wed Oct 7
2:10pm
Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology
with Pfizer, Nucleai, Gilead Sciences +1 more
Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine
Panel
Wed Oct 7
3:10pm
Bolstering Scalable Commercial Drug-Diagnostic Strategies to Ensure Equitable Solutions for Global Precision Oncology Applications
with Rigel Pharmaceuticals
Drug–diagnostic commercialization & access
Panel
Thu Oct 8
9:00am
Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers
with Johnson & Johnson Innovative Medicine, AstraZeneca
Drug–diagnostic commercialization & access
GSK
London, UK
gsk.com
Large pharma
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, respiratory, immunology and oncology.
Panel
Tue Oct 6
6:10pm
Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation
with Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, BLOODPAC
Liquid biopsy & MRDClinical & companion diagnostic development
Panel
Wed Oct 7
9:00am
Applying AI & Advanced Data Analytics to Transform Biomarker Discovery & Clinical Trial Strategy for Improved Precision Medicine Programs
with Sanofi, Novartis
Multimodal & AI-enabled precision medicineBiomarker discovery & translation
Panel
Wed Oct 7
12:10pm
Building the Clinical & Commercial Ecosystem for AI-Enabled Precision Pathology
with Panakeia, Friends of Cancer Research
Digital pathology & spatial biomarkersDrug–diagnostic commercialization & access
Talk
Thu Oct 8
9:50am
When a Drug Program Expects Multiple Global Dx Partners: Considerations for Master CDx Agreements
Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access
AbbVie
North Chicago, IL
abbvie.com
Large pharma
Global pharmaceutical company with medicines in immunology, oncology, neuroscience and eye care, including antibody-drug conjugates for cancer.
Panel
Tue Oct 6
2:00pm
Single-Cell Becomes a Reality: The Next Generation of Therapy Selection Biomarkers
with Foundation Medicine, One Biosciences
Biomarker discovery & translation
Talk
Wed Oct 7
11:50am
Strategic Considerations for Global Precision Medicine ADC Biomarker Launches
Drug–diagnostic commercialization & accessClinical & companion diagnostic development
Talk
Wed Oct 7
2:10pm
From Assay to Asset: How End‑to‑End Companion Diagnostic Partnerships Deliver Strategic Platform Selection, Clinical Development Alignment, & Reliable Execution
with Abbott
Clinical & companion diagnostic development
Agilent
Santa Clara, CA
◇Expertise Partner
agilent.com/en/solutions/companion-diagnostics
Diagnostics & testing labsExpertise Partner
Life science and diagnostics company whose companion diagnostics group co-develops assays with pharma partners; co-developed HercepTest, an early companion diagnostic, in 1998.
Panel
Tue Oct 6
12:30pm
Companion Diagnostics from Biomarker Discovery to Global Launch: Building Better Partnerships Across Science, Regulation, & Commercialization
with Tango Therapeutics, Merck
Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access
Panel
Wed Oct 7
3:10pm
Innovating Global Rx-Dx Trial Pathways Through Strategic & Compliant Co-Development Partnerships to Deliver Harmonized Precision Medicine Solutions
with Bayer, Astellas, Pfizer
Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access
Abbott
Abbott Park, IL
◇Program Partner
abbott.com
Diagnostics & testing labsProgram Partner
Healthcare company with a broad in vitro diagnostics portfolio; its molecular diagnostics unit makes oncology FISH and PCR assays and develops companion diagnostics.
Talk
Wed Oct 7
2:10pm
From Assay to Asset: How End‑to‑End Companion Diagnostic Partnerships Deliver Strategic Platform Selection, Clinical Development Alignment, & Reliable Execution
with AbbVie
Clinical & companion diagnostic development
Labcorp
Burlington, NC
◇Expertise Partner
labcorp.com
CROs & central labsExpertise Partner
Laboratory services company running diagnostic testing and drug development lab work, including companion diagnostic development services for pharma.
Panel
Thu Oct 8
2:00pm
Fit-for-Purpose CDx Strategies: Matching Testing Approaches to Development & Patient Access Needs​
with Johnson & Johnson Innovative Medicine
Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access

Explore the full World CDx 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full World CDx 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from companies at World CDx 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

When and where was World CDx 2026?

16th World Clinical Biomarkers & Companion Diagnostics Summit ran October 5–8, 2026, at The Westin Boston Seaport District in Boston, MA.

What conference is this?

World CDx is an annual clinical biomarkers and companion diagnostics summit, held October 5–8, 2026 at The Westin Boston Seaport District. It brings together biomarker, translational medicine and companion diagnostics leaders from pharma and biotech with the diagnostics companies, testing labs and technology providers they partner with, across five streams: biomarker discovery and translation, clinical and companion diagnostic development, drug–diagnostic commercialization and adoption, digital pathology and spatial biomarkers, and multimodal and AI-enabled precision medicine. The meeting has ended; this guide is its record.

What is in this guide?

Every organization we can place at World CDx 2026: 135 speakers from the public speaker pages (97 talks, panels and chaired sessions) rolled up to their companies and institutions, and the 67 partners from the public partner list with their tier — 120 organizations in one list. Speakers appear as job titles, never by name. The organizers publish the full agenda only as a gated download, so a session is listed as each speaker’s page gives it: its day, time and title. There is no public attendee list and no booth numbers.

How are organizations typed?

By the role an organization plays in precision medicine: drug developers (large pharma and biotech), diagnostics companies and testing labs, then instrument and reagent companies, software, data and AI companies, CROs and central labs, and consultancies and other services — and academic, government and non-profit bodies. The topic filters are judged from each session’s title.

How current is it?

Pulled from the public speaker pages and partner list on October 8, 2026, the meeting’s last day.

Browse World CDx 2026 by

Organization type
Topic
Everyone

Organizations with their own page

85 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by World CDx or its organizers. Submit a correction